There is currently no generic version of Praluent (alirocumab) available on the market. Praluent is a brand-name prescription medication used to lower LDL cholesterol [1].
When can I expect a generic version of Praluent?
The patent expiry dates for Praluent are a key factor in determining when a generic version could become available. Information from DrugPatentWatch.com indicates that patent protections for Praluent are in place for several years. Specifically, the earliest key patent expiry is listed for 2031 [2]. However, the actual launch of a generic can depend on various factors, including patent litigation and regulatory approvals [3].
What is Praluent used for?
Praluent is a PCSK9 inhibitor that works by helping the liver remove more LDL cholesterol from the blood [1]. It is prescribed for adults with certain types of high cholesterol, including those with primary hyperlipidemia or heterozygous familial hypercholesterolemia, and is often used in addition to diet and statin therapy [1].
How does Praluent work?
Praluent contains the active ingredient alirocumab, which is a monoclonal antibody. It targets and inhibits the PCSK9 protein. When PCSK9 is inhibited, the liver has more LDL receptors available to clear cholesterol from the bloodstream, thus lowering LDL cholesterol levels [1].
What are the alternatives to Praluent?
For lowering LDL cholesterol, other treatment options include statins, ezetimibe, and bile acid sequestrants [1]. Praluent is generally considered when these other medications are not sufficient or cannot be tolerated.
Who makes Praluent?
Praluent is manufactured by Sanofi and Regeneron Pharmaceuticals [1].